TABLE OF CONTENTS
1 EXECUTIVE SUMMARY
2 MARKET INTRODUCTION
2.1 DEFINITION
2.2 SCOPE OF THE STUDY
2.3 RESEARCH OBJECTIVE
2.4 MARKET STRUCTURE
3 RESEARCH METHODOLOGY
3.1 OVERVIEW
3.2 DATA FLOW
3.2.1 DATA MINING PROCESS
3.3 PURCHASED DATABASE:
3.4 SECONDARY SOURCES:
3.4.1 SECONDARY RESEARCH DATA FLOW:
3.5 PRIMARY RESEARCH:
3.5.1 PRIMARY RESEARCH DATA FLOW:
3.6 APPROACHES FOR MARKET SIZE ESTIMATION:
3.6.1 REVENUE ANALYSIS APPROACH
3.7 DATA FORECASTING
3.7.1 DATA FORECASTING TYPE
3.8 DATA MODELING
3.8.1 MICROECONOMIC FACTOR ANALYSIS:
3.8.2 DATA MODELING:
3.9 TEAMS AND ANALYST CONTRIBUTION
4 MARKET DYNAMICS
4.1 INTRODUCTION
4.2 DRIVERS
4.2.1 GROWING INCIDENCES AND PREVALENCE OF CANCER AND RARE DISORDERS
4.2.2 INCREASING APPROVAL FOR GENE THERAPY PRODUCTS
4.2.3 FAVOURABLE GOVERNMENT SUPPORT FOR GENE THERAPY
4.3 RESTRAINTS
4.3.1 CLINICAL TRIAL FAILURE ASSOCIATED WITH GENE THERAPY
4.3.2 CHALLENGES ASSOCIATED WITH GENE THERAPY DELIVERY
4.4 OPPORTUNITY
4.4.1 GROWING INVESTMENT IN THE FIELD OF GENE THERAPY
4.4.2 ONGOING CLINICAL TRIALS ASSOCIATED WITH GENE THERAPY
5 MARKET FACTOR ANALYSIS
5.1 PORTER'S FIVE FORCES MODEL
5.1.1 THREAT OF NEW ENTRANTS
5.1.2 BARGAINING POWER OF SUPPLIERS
5.1.3 THREAT OF SUBSTITUTES
5.1.4 BARGAINING POWER OF BUYERS
5.1.5 INTENSITY OF RIVALRY
5.2 IMPACT OF COVID-19 ON THE GLOBAL GENE THERAPY MARKET
6 GLOBAL GENE THERAPY MARKET, BY VECTOR TYPE
6.1 OVERVIEW
6.2 VIRAL VECTOR
6.2.1 LENTIVIRAL VECTORS (LVVS)
6.2.2 RETROVIRUS VECTORS
6.2.3 ADENOVIRAL VECTORS (ADVS)
6.2.4 ADENO-ASSOCIATED VIRAL VECTORS (AAVS)
6.3 NON-VIRAL VECTOR
6.3.1 PHYSICAL VECTOR
6.3.2 CHEMICAL VECTOR
7 GLOBAL GENE THERAPY MARKET, BY GENE TYPE
7.1 OVERVIEW
7.2 ANTIGEN
7.3 CYTOKINE
7.4 TUMOR SUPPRESSOR
7.5 SUICIDE
7.6 DEFICIENCY
7.7 GROWTH FACTORS
7.8 RECEPTORS
7.9 OTHERS
8 GLOBAL GENE THERAPY MARKET, BY APPLICATION
8.1 OVERVIEW
8.2 ONCOLOGICAL DISORDERS
8.3 RARE DISEASES
8.4 CARDIOVASCULAR DISEASES
8.5 NEUROLOGICAL DISORDERS
8.6 INFECTIOUS DISEASES
8.7 OTHERS
9 GLOBAL GENE THERAPY MARKET, BY DELIVERY METHOD
9.1 OVERVIEW
9.2 IN VIVO GENE THERAPY
9.3 EX VIVO GENE THERAPY
10 GLOBAL GENE THERAPY MARKET, BY REGION
10.1 OVERVIEW
10.2 NORTH AMERICA
10.2.1 US
10.2.2 CANADA
10.3 EUROPE
10.3.1 GERMANY
10.3.2 FRANCE
10.3.3 UK
10.3.4 ITALY
10.3.5 SPAIN
10.3.6 REST OF EUROPE
10.4 ASIA-PACIFIC
10.4.1 CHINA
10.4.2 INDIA
10.4.3 JAPAN
10.4.4 SOUTH KOREA
10.4.5 AUSTRALIA
10.4.6 REST OF ASIA-PACIFIC
10.5 REST OF THE WORLD
10.5.1 MIDDLE EAST & AFRICA
10.5.2 SOUTH AMERICA
11 COMPETITIVE LANDSCAPE
11.1 INTRODUCTION
11.2 MARKET SHARE ANALYSIS, 2024
11.3 COMPETITOR DASHBOARD
11.4 PUBLIC PLAYERS STOCK SUMMARY
11.5 COMPARATIVE ANALYSIS: KEY PLAYERS FINANICAL
11.6 KEY DEVELOPMENTS & GROWTH STRATEGIES
11.6.1 PRODUCT APPROVAL/ PRODUCT LAUNCH
11.6.2 ACQUISITION/ EXPANSION
11.6.3 AGREEMENT/PARTNERSHIP/COLLABORATION
12 COMPANY PROFILES
12.1 BRISTOL-MYERS SQUIBB COMPANY
12.1.1 COMPANY OVERVIEW
12.1.2 FINANCIAL OVERVIEW
12.1.3 PRODUCTS OFFERED
12.1.4 KEY DEVELOPMENTS
12.1.5 SWOT ANALYSIS
12.1.6 KEY STRATEGIES
12.2 LONZA
12.2.1 COMPANY OVERVIEW
12.2.2 FINANCIAL OVERVIEW
12.2.3 PRODUCT OFFERED
12.2.4 KEY DEVELOPMENTS
12.2.5 SWOT ANALYSIS
12.2.6 KEY STRATEGIES
12.3 UNIQURE N.V.
12.3.1 COMPANY OVERVIEW
12.3.2 FINANCIAL OVERVIEW
12.3.3 PRODUCTS OFFERED
12.3.4 KEY DEVELOPMENTS
12.3.5 SWOT ANALYSIS
12.3.6 KEY STRATEGIES
12.4 BLUEBIRD BIO, INC.
12.4.1 COMPANY OVERVIEW
12.4.2 PRODUCTS OFFERED
12.4.3 KEY DEVELOPMENTS
12.4.4 KEY STRATEGIES
12.5 ORCHARD THERAPEUTICS PLC
12.5.1 COMPANY OVERVIEW
12.5.2 FINANCIAL OVERVIEW
12.5.3 PRODUCTS OFFERED
12.5.4 KEY DEVELOPMENTS
12.5.5 KEY STRATEGIES
12.6 GENSIGHT BIOLOGICS
12.6.1 COMPANY OVERVIEW
12.6.2 PRODUCTS OFFERED
12.6.3 KEY DEVELOPMENTS
12.6.4 KEY STRATEGIES
12.7 NOVARTIS AG
12.7.1 COMPANY OVERVIEW
12.7.2 FINANCIAL OVERVIEW
12.7.3 PRODUCTS OFFERED
12.7.4 KEY DEVELOPMENTS
12.7.5 SWOT ANALYSIS
12.7.6 KEY STRATEGIES
12.8 AMGEN INC.
12.8.1 COMPANY OVERVIEW
12.8.2 FINANCIAL OVERVIEW
12.8.3 PRODUCTS OFFERED
12.8.4 KEY DEVELOPMENTS
12.8.5 SWOT ANALYSIS
12.8.6 KEY STRATEGIES
12.9 SAREPTA THERAPEUTICS INC.
12.9.1 COMPANY OVERVIEW
12.9.2 FINANCIAL OVERVIEW
12.9.3 PRODUCT OFFERED
12.9.4 KEY DEVELOPMENTS
12.9.5 KEY STRATEGIES
12.10 SPARK THERAPEUTICS, INC.
12.10.1 COMPANY OVERVIEW
12.10.1 FINANCIAL OVERVIEW
12.10.2 PRODUCTS OFFERED
12.10.3 KEY DEVELOPMENTS
12.10.4 KEY STRATEGIES
12.11 DATA CITATIONS
Â
Â
Â
Â
Â
Â
LIST OF TABLES
TABLE 1 QFD MODELING FOR MARKET SHARE ASSESSMENT
TABLE 2 GLOBAL GENE THERAPY MARKET, BY VECTOR TYPE, 2019–2035 (USD BILLION)
TABLE 3 GLOBAL GENE THERAPY MARKET, FOR VIRAL VECTOR, BY REGION, 2019–2035 (USD BILLION)
TABLE 4 GLOBAL GENE THERAPY MARKET, FOR VIRAL VECTOR, BY TYPE, 2019–2035 (USD BILLION)
TABLE 5 GLOBAL GENE THERAPY MARKET, FOR LENTIVIRAL VECTORS (LVVS), BY REGION, 2019–2035 (USD BILLION)
TABLE 6 GLOBAL GENE THERAPY MARKET, FOR RETROVIRUS VECTORS, BY REGION, 2019–2035 (USD BILLION)
TABLE 7 GLOBAL GENE THERAPY MARKET, FOR ADENOVIRAL VECTORS (ADVS), BY REGION, 2019–2035 (USD BILLION)
TABLE 8 GLOBAL GENE THERAPY MARKET, FOR ADENO-ASSOCIATED VIRAL VECTORS (AAVS), BY REGION, 2019–2035 (USD BILLION)
TABLE 9 GLOBAL GENE THERAPY MARKET, FOR NON-VIRAL VECTOR, BY REGION, 2019–2035 (USD BILLION)
TABLE 10 GLOBAL GENE THERAPY MARKET, FOR NON- VIRAL VECTORS, BY TYPE, 2019–2035 (USD BILLION)
TABLE 11 GLOBAL GENE THERAPY MARKET, FOR PHYSICAL VECTOR, BY REGION, 2019–2035 (USD BILLION)
TABLE 12 GLOBAL GENE THERAPY MARKET, FOR CHEMICAL VECTOR, BY REGION, 2019–2035 (USD BILLION)
TABLE 13 GLOBAL GENE THERAPY MARKET, BY GENE TYPE, 2019–2035 (USD BILLION)
TABLE 14 GLOBAL GENE THERAPY MARKET, FOR ANTIGEN, BY REGION, 2019–2035 (USD BILLION)
TABLE 15 GLOBAL GENE THERAPY MARKET, FOR CYTOKINE, BY REGION, 2019–2035 (USD BILLION)
TABLE 16 GLOBAL GENE THERAPY MARKET, FOR TUMOR SUPPRESSOR, BY REGION, 2019–2035 (USD BILLION)
TABLE 17 GLOBAL GENE THERAPY MARKET, FOR SUICIDE, BY REGION, 2019–2035 (USD BILLION)
TABLE 18 GLOBAL GENE THERAPY MARKET, FOR DEFICIENCY, BY REGION, 2019–2035 (USD BILLION)
TABLE 19 GLOBAL GENE THERAPY MARKET, FOR GROWTH FACTORS, BY REGION, 2019–2035 (USD BILLION)
TABLE 20 GLOBAL GENE THERAPY MARKET, FOR RECEPTORS, BY REGION, 2019–2035 (USD BILLION)
TABLE 21 GLOBAL GENE THERAPY MARKET, FOR OTHERS, BY REGION, 2019–2035 (USD BILLION)
TABLE 22 GLOBAL GENE THERAPY MARKET, BY APPLICATION, 2019–2035 (USD BILLION)
TABLE 23 GLOBAL GENE THERAPY MARKET, FOR ONCOLOGICAL DISORDERS, BY REGION, 2019–2035 (USD BILLION)
TABLE 24 GLOBAL GENE THERAPY MARKET, FOR RARE DISEASES, BY REGION, 2019–2035 (USD BILLION)
TABLE 25 GLOBAL GENE THERAPY MARKET, FOR CARDIOVASCULAR DISEASES, BY REGION, 2019–2035 (USD BILLION)
TABLE 26 GLOBAL GENE THERAPY MARKET, FOR NEUROLOGICAL DISORDERS, BY REGION, 2019–2035 (USD BILLION)
TABLE 27 GLOBAL GENE THERAPY MARKET, FOR INFECTIOUS DISEASES, BY REGION, 2019–2035 (USD BILLION)
TABLE 28 GLOBAL GENE THERAPY MARKET, FOR OTHERS, BY REGION, 2019–2035 (USD BILLION)
TABLE 29 GLOBAL GENE THERAPY MARKET, BY DELIVERY METHOD, 2019–2035 (USD BILLION)
TABLE 30 GLOBAL GENE THERAPY MARKET, FOR IN VIVO GENE THERAPY, BY REGION, 2019–2035 (USD BILLION)
TABLE 31 GLOBAL GENE THERAPY MARKET, FOR EX VIVO GENE THERAPY, BY REGION, 2019–2035 (USD BILLION)
TABLE 32 GLOBAL GENE THERAPY MARKET, BY REGION, 2019–2035 (USD BILLION)
TABLE 33 NORTH AMERICA: GENE THERAPY MARKET, BY COUNTRY, 2019–2035 (USD BILLION)
TABLE 34 NORTH AMERICA: GENE THERAPY MARKET, BY VECTOR TYPE, 2019–2035 (USD BILLION)
TABLE 35 NORTH AMERICA: GENE THERAPY MARKET, FOR VIRAL VECTOR, BY TYPE, 2019–2035 (USD BILLION)
TABLE 36 NORTH AMERICA: GENE THERAPY MARKET, FOR NON-VIRAL VECTOR, BY TYPE, 2019–2035 (USD BILLION)
TABLE 37 NORTH AMERICA: GENE THERAPY MARKET, BY GENE TYPE, 2019–2035 (USD BILLION)
TABLE 38 NORTH AMERICA: GENE THERAPY MARKET, BY APPLICATION, 2019–2035 (USD BILLION)
TABLE 39 NORTH AMERICA: GENE THERAPY MARKET, BY DELIVERY METHOD, 2019–2035 (USD BILLION)
TABLE 40 US: GENE THERAPY MARKET, BY VECTOR TYPE, 2019–2035 (USD BILLION)
TABLE 41 US: GENE THERAPY MARKET, FOR VIRAL VECTOR, BY TYPE, 2019–2035 (USD BILLION)
TABLE 42 US: GENE THERAPY MARKET, FOR NON-VIRAL VECTOR, BY TYPE, 2019–2035 (USD BILLION)
TABLE 43 US: GENE THERAPY MARKET, BY GENE TYPE, 2019–2035 (USD BILLION)
TABLE 44 US: GENE THERAPY MARKET, BY APPLICATION, 2019–2035 (USD BILLION)
TABLE 45 US: GENE THERAPY MARKET, BY DELIVERY METHOD, 2019–2035 (USD BILLION)
TABLE 46 CANADA: GENE THERAPY MARKET, BY VECTOR TYPE, 2019–2035 (USD BILLION)
TABLE 47 CANADA: GENE THERAPY MARKET, FOR VIRAL VECTOR, BY TYPE, 2019–2035 (USD BILLION)
TABLE 48 CANADA: GENE THERAPY MARKET, FOR NON-VIRAL VECTOR, BY TYPE, 2019–2035 (USD BILLION)
TABLE 49 CANADA: GENE THERAPY MARKET, BY GENE TYPE, 2019–2035 (USD BILLION)
TABLE 50 CANADA: GENE THERAPY MARKET, BY APPLICATION, 2019–2035 (USD BILLION)
TABLE 51 CANADA: GENE THERAPY MARKET, BY DELIVERY METHOD, 2019–2035 (USD BILLION)
TABLE 52 EUROPE: GENE THERAPY MARKET, BY COUNTRY, 2019–2035 (USD BILLION)
TABLE 53 EUROPE: GENE THERAPY MARKET, BY VECTOR TYPE, 2019–2035 (USD BILLION)
TABLE 54 EUROPE: GENE THERAPY MARKET, FOR VIRAL VECTOR, BY TYPE, 2019–2035 (USD BILLION)
TABLE 55 EUROPE: GENE THERAPY MARKET, FOR NON-VIRAL VECTOR, BY TYPE, 2019–2035 (USD BILLION)
TABLE 56 EUROPE: GENE THERAPY MARKET, BY GENE TYPE, 2019–2035 (USD BILLION)
TABLE 57 EUROPE: GENE THERAPY MARKET, BY APPLICATION, 2019–2035 (USD BILLION)
TABLE 58 EUROPE: GENE THERAPY MARKET, BY DELIVERY METHOD, 2019–2035 (USD BILLION)
TABLE 59 GERMANY: GENE THERAPY MARKET, BY VECTOR TYPE, 2019–2035 (USD BILLION)
TABLE 60 GERMANY: GENE THERAPY MARKET, FOR VIRAL VECTOR, BY TYPE, 2019–2035 (USD BILLION)
TABLE 61 GERMANY: GENE THERAPY MARKET, FOR NON-VIRAL VECTOR, BY TYPE, 2019–2035 (USD BILLION)
TABLE 62 GERMANY: GENE THERAPY MARKET, BY GENE TYPE, 2019–2035 (USD BILLION)
TABLE 63 GERMANY: GENE THERAPY MARKET, BY APPLICATION, 2019–2035 (USD BILLION)
TABLE 64 GERMANY: GENE THERAPY MARKET, BY DELIVERY METHOD, 2019–2035 (USD BILLION)
TABLE 65 FRANCE: GENE THERAPY MARKET, BY VECTOR TYPE, 2019–2035 (USD BILLION)
TABLE 66 FRANCE: GENE THERAPY MARKET, FOR VIRAL VECTOR, BY TYPE, 2019–2035 (USD BILLION)
TABLE 67 FRANCE: GENE THERAPY MARKET, FOR NON-VIRAL VECTOR, BY TYPE, 2019–2035 (USD BILLION)
TABLE 68 FRANCE: GENE THERAPY MARKET, BY GENE TYPE, 2019–2035 (USD BILLION)
TABLE 69 FRANCE: GENE THERAPY MARKET, BY APPLICATION, 2019–2035 (USD BILLION)
TABLE 70 FRANCE: GENE THERAPY MARKET, BY DELIVERY METHOD, 2019–2035 (USD BILLION)
TABLE 71 UK: GENE THERAPY MARKET, BY VECTOR TYPE, 2019–2035 (USD BILLION)
TABLE 72 UK: GENE THERAPY MARKET, FOR VIRAL VECTOR, BY TYPE, 2019–2035 (USD BILLION)
TABLE 73 UK: GENE THERAPY MARKET, FOR NON-VIRAL VECTOR, BY TYPE, 2019–2035 (USD BILLION)
TABLE 74 UK: GENE THERAPY MARKET, BY GENE TYPE, 2019–2035 (USD BILLION)
TABLE 75 UK: GENE THERAPY MARKET, BY APPLICATION, 2019–2035 (USD BILLION)
TABLE 76 UK: GENE THERAPY MARKET, BY DELIVERY METHOD, 2019–2035 (USD BILLION)
TABLE 77 ITALY: GENE THERAPY MARKET, BY VECTOR TYPE, 2019–2035 (USD BILLION)
TABLE 78 ITALY: GENE THERAPY MARKET, FOR VIRAL VECTOR, BY TYPE, 2019–2035 (USD BILLION)
TABLE 79 ITALY: GENE THERAPY MARKET, FOR NON-VIRAL VECTOR, BY TYPE, 2019–2035 (USD BILLION)
TABLE 80 ITALY: GENE THERAPY MARKET, BY GENE TYPE, 2019–2035 (USD BILLION)
TABLE 81 ITALY: GENE THERAPY MARKET, BY APPLICATION, 2019–2035 (USD BILLION)
TABLE 82 ITALY: GENE THERAPY MARKET, BY DELIVERY METHOD, 2019–2035 (USD BILLION)
TABLE 83 SPAIN: GENE THERAPY MARKET, BY VECTOR TYPE, 2019–2035 (USD BILLION)
TABLE 84 SPAIN: GENE THERAPY MARKET, FOR VIRAL VECTOR, BY TYPE, 2019–2035 (USD BILLION)
TABLE 85 SPAIN: GENE THERAPY MARKET, FOR NON-VIRAL VECTOR, BY TYPE, 2019–2035 (USD BILLION)
TABLE 86 SPAIN: GENE THERAPY MARKET, BY GENE TYPE, 2019–2035 (USD BILLION)
TABLE 87 SPAIN: GENE THERAPY MARKET, BY APPLICATION, 2019–2035 (USD BILLION)
TABLE 88 SPAIN: GENE THERAPY MARKET, BY DELIVERY METHOD, 2019–2035 (USD BILLION)
TABLE 89 REST OF EUROPE: GENE THERAPY MARKET, BY VECTOR TYPE, 2019–2035 (USD BILLION)
TABLE 90 REST OF EUROPE: GENE THERAPY MARKET, FOR VIRAL VECTOR, BY TYPE, 2019–2035 (USD BILLION)
TABLE 91 REST OF EUROPE: GENE THERAPY MARKET, FOR NON-VIRAL VECTOR, BY TYPE, 2019–2035 (USD BILLION)
TABLE 92 REST OF EUROPE: GENE THERAPY MARKET, BY GENE TYPE, 2019–2035 (USD BILLION)
TABLE 93 REST OF EUROPE: GENE THERAPY MARKET, BY APPLICATION, 2019–2035 (USD BILLION)
TABLE 94 REST OF EUROPE: GENE THERAPY MARKET, BY DELIVERY METHOD, 2019–2035 (USD BILLION)
TABLE 95 ASIA-PACIFIC: GENE THERAPY MARKET, BY COUNTRY, 2019–2035 (USD BILLION)
TABLE 96 ASIA-PACIFIC: GENE THERAPY MARKET, BY VECTOR TYPE, 2019–2035 (USD BILLION)
TABLE 97 ASIA-PACIFIC: GENE THERAPY MARKET, FOR VIRAL VECTOR, BY TYPE, 2019–2035 (USD BILLION)
TABLE 98 ASIA-PACIFIC: GENE THERAPY MARKET, FOR NON-VIRAL VECTOR, BY TYPE, 2019–2035 (USD BILLION)
TABLE 99 ASIA-PACIFIC: GENE THERAPY MARKET, BY GENE TYPE, 2019–2035 (USD BILLION)
TABLE 100 ASIA-PACIFIC: GENE THERAPY MARKET, BY APPLICATION, 2019–2035 (USD BILLION)
TABLE 101 ASIA-PACIFIC: GENE THERAPY MARKET, BY DELIVERY METHOD, 2019–2035 (USD BILLION)
TABLE 102 CHINA: GENE THERAPY MARKET, BY VECTOR TYPE, 2019–2035 (USD BILLION)
TABLE 103 CHINA: GENE THERAPY MARKET, FOR VIRAL VECTOR, BY TYPE, 2019–2035 (USD BILLION)
TABLE 104 CHINA: GENE THERAPY MARKET, FOR NON-VIRAL VECTOR, BY TYPE, 2019–2035 (USD BILLION)
TABLE 105 CHINA: GENE THERAPY MARKET, BY GENE TYPE, 2019–2035 (USD BILLION)
TABLE 106 CHINA: GENE THERAPY MARKET, BY APPLICATION, 2019–2035 (USD BILLION)
TABLE 107 CHINA: GENE THERAPY MARKET, BY DELIVERY METHOD, 2019–2035 (USD BILLION)
TABLE 108 INDIA: GENE THERAPY MARKET, BY VECTOR TYPE, 2019–2035 (USD BILLION)
TABLE 109 INDIA: GENE THERAPY MARKET, FOR VIRAL VECTOR, BY TYPE, 2019–2035 (USD BILLION)
TABLE 110 INDIA: GENE THERAPY MARKET, FOR NON-VIRAL VECTOR, BY TYPE, 2019–2035 (USD BILLION)
TABLE 111 INDIA: GENE THERAPY MARKET, BY GENE TYPE, 2019–2035 (USD BILLION)
TABLE 112 INDIA: GENE THERAPY MARKET, BY APPLICATION, 2019–2035 (USD BILLION)
TABLE 113 INDIA: GENE THERAPY MARKET, BY DELIVERY METHOD, 2019–2035 (USD BILLION)
TABLE 114 JAPAN: GENE THERAPY MARKET, BY VECTOR TYPE, 2019–2035 (USD BILLION)
TABLE 115 JAPAN: GENE THERAPY MARKET, FOR VIRAL VECTOR, BY TYPE, 2019–2035 (USD BILLION)
TABLE 116 JAPAN: GENE THERAPY MARKET, FOR NON-VIRAL VECTOR, BY TYPE, 2019–2035 (USD BILLION)
TABLE 117 JAPAN: GENE THERAPY MARKET, BY GENE TYPE, 2019–2035 (USD BILLION)
TABLE 118 JAPAN: GENE THERAPY MARKET, BY APPLICATION, 2019–2035 (USD BILLION)
TABLE 119 JAPAN: GENE THERAPY MARKET, BY DELIVERY METHOD, 2019–2035 (USD BILLION)
TABLE 120 SOUTH KOREA: GENE THERAPY MARKET, BY VECTOR TYPE, 2019–2035 (USD BILLION)
TABLE 121 SOUTH KOREA: GENE THERAPY MARKET, FOR VIRAL VECTOR, BY TYPE, 2019–2035 (USD BILLION)
TABLE 122 SOUTH KOREA: GENE THERAPY MARKET, FOR NON-VIRAL VECTOR, BY TYPE, 2019–2035 (USD BILLION)
TABLE 123 SOUTH KOREA: GENE THERAPY MARKET, BY GENE TYPE, 2019–2035 (USD BILLION)
TABLE 124 SOUTH KOREA: GENE THERAPY MARKET, BY APPLICATION, 2019–2035 (USD BILLION)
TABLE 125 SOUTH KOREA: GENE THERAPY MARKET, BY DELIVERY METHOD, 2019–2035 (USD BILLION)
TABLE 126 AUSTRALIA: GENE THERAPY MARKET, BY VECTOR TYPE, 2019–2035 (USD BILLION)
TABLE 127 AUSTRALIA: GENE THERAPY MARKET, FOR VIRAL VECTOR, BY TYPE, 2019–2035 (USD BILLION)
TABLE 128 AUSTRALIA: GENE THERAPY MARKET, FOR NON-VIRAL VECTOR, BY TYPE, 2019–2035 (USD BILLION)
TABLE 129 AUSTRALIA: GENE THERAPY MARKET, BY GENE TYPE, 2019–2035 (USD BILLION)
TABLE 130 AUSTRALIA: GENE THERAPY MARKET, BY APPLICATION, 2019–2035 (USD BILLION)
TABLE 131 AUSTRALIA: GENE THERAPY MARKET, BY DELIVERY METHOD, 2019–2035 (USD BILLION)
TABLE 132 REST OF ASIA-PACIFIC: GENE THERAPY MARKET, BY VECTOR TYPE, 2019–2035 (USD BILLION)
TABLE 133 REST OF ASIA-PACIFIC: GENE THERAPY MARKET, FOR VIRAL VECTOR, BY TYPE, 2019–2035 (USD BILLION)
TABLE 134 REST OF ASIA-PACIFIC: GENE THERAPY MARKET, FOR NON-VIRAL VECTOR, BY TYPE, 2019–2035 (USD BILLION)
TABLE 135 REST OF ASIA-PACIFIC: GENE THERAPY MARKET, BY GENE TYPE, 2019–2035 (USD BILLION)
TABLE 136 REST OF ASIA-PACIFIC: GENE THERAPY MARKET, BY APPLICATION, 2019–2035 (USD BILLION)
TABLE 137 REST OF ASIA-PACIFIC: GENE THERAPY MARKET, BY DELIVERY METHOD, 2019–2035 (USD BILLION)
TABLE 138 REST OF THE WORLD: GENE THERAPY MARKET, BY COUNTRY, 2019–2035 (USD BILLION)
TABLE 139 REST OF THE WORLD: GENE THERAPY MARKET, BY VECTOR TYPE, 2019–2035 (USD BILLION)
TABLE 140 REST OF THE WORLD: GENE THERAPY MARKET, FOR VIRAL VECTOR, BY TYPE, 2019–2035 (USD BILLION)
TABLE 141 REST OF THE WORLD: GENE THERAPY MARKET, FOR NON-VIRAL VECTOR, BY TYPE, 2019–2035 (USD BILLION)
TABLE 142 REST OF THE WORLD: GENE THERAPY MARKET, BY GENE TYPE, 2019–2035 (USD BILLION)
TABLE 143 REST OF THE WORLD: GENE THERAPY MARKET, BY APPLICATION, 2019–2035 (USD BILLION)
TABLE 144 REST OF THE WORLD: GENE THERAPY MARKET, BY DELIVERY METHOD, 2019–2035 (USD BILLION)
TABLE 145 MIDDLE EAST & AFRICA: GENE THERAPY MARKET, BY VECTOR TYPE, 2019–2035 (USD BILLION)
TABLE 146 MIDDLE EAST & AFRICA: GENE THERAPY MARKET, FOR VIRAL VECTOR, BY TYPE, 2019–2035 (USD BILLION)
TABLE 147 MIDDLE EAST & AFRICA: GENE THERAPY MARKET, FOR NON-VIRAL VECTOR, BY TYPE, 2019–2035 (USD BILLION)
TABLE 148 MIDDLE EAST & AFRICA: GENE THERAPY MARKET, BY GENE TYPE, 2019–2035 (USD BILLION)
TABLE 149 MIDDLE EAST & AFRICA: GENE THERAPY MARKET, BY APPLICATION, 2019–2035 (USD BILLION)
TABLE 150 MIDDLE EAST & AFRICA: GENE THERAPY MARKET, BY DELIVERY METHOD, 2019–2035 (USD BILLION)
TABLE 151 SOUTH AMERICA: GENE THERAPY MARKET, BY VECTOR TYPE, 2019–2035 (USD BILLION)
TABLE 152 SOUTH AMERICA: GENE THERAPY MARKET, FOR VIRAL VECTOR, BY TYPE, 2019–2035 (USD BILLION)
TABLE 153 SOUTH AMERICA: GENE THERAPY MARKET, FOR NON-VIRAL VECTOR, BY TYPE, 2019–2035 (USD BILLION)
TABLE 154 SOUTH AMERICA: GENE THERAPY MARKET, BY GENE TYPE, 2019–2035 (USD BILLION)
TABLE 155 SOUTH AMERICA: GENE THERAPY MARKET, BY APPLICATION, 2019–2035 (USD BILLION)
TABLE 156 SOUTH AMERICA: GENE THERAPY MARKET, BY DELIVERY METHOD, 2019–2035 (USD BILLION)
TABLE 157 PUBLIC PLAYERS STOCK SUMMARY
TABLE 158 PRODUCT APROVAL/ PRODUCT LAUNCH
TABLE 159 ACQUISITION/ EXPANSION
TABLE 160 AGREEMENT/PARTNERSHIP/COLLABORATION
TABLE 161 BRISTOL-MYERS SQUIBB COMPANY: PRODUCT OFFERED
TABLE 162 BRISTOL-MYERS SQUIBB COMPANY: KEY DEVELOPMENTS
TABLE 163 LONZA: PRODUCTS OFFERED
TABLE 164 LONZA: KEY DEVELOPMENTS
TABLE 165 UNIQURE N.V.: PRODUCTS OFFERED
TABLE 166 UNIQURE N.V.: KEY DEVELOPMENTS
TABLE 167 BLUEBIRD BIO, INC.: PRODUCTS OFFERED
TABLE 168 BLUEBIRD BIO, INC.: KEY DEVELOPMENTS
TABLE 169 ORCHARD THERAPEUTICS PLC: PRODUCTS OFFERED
TABLE 170 ORCHARD THERAPEUTICS PLC: KEY DEVELOPMENTS
TABLE 171 GENSIGHT BIOLOGICS: PRODUCTS OFFERED
TABLE 172 GENSIGHT BIOLOGICS: KEY DEVELOPMENTS
TABLE 173 NOVARTIS AG: PRODUCTS OFFERED
TABLE 174 NOVARTIS AG: KEY DEVELOPMENTS
TABLE 175 AMGEN INC.: PRODUCTS OFFERED
TABLE 176 SAREPTA THERAPEUTICS INC.: PRODUCTS OFFERED
TABLE 177 SAREPTA THERAPEUTICS INC.: KEY DEVELOPMENTS
TABLE 178 SPARK THERAPEUTICS, INC.: PRODUCTS OFFERED
TABLE 179 SPARK THERAPEUTICS, INC.: KEY DEVELOPMENTS
Â
Â
Â
Â
Â
LIST OF FIGURES
FIGURE 1 GLOBAL GENE THERAPY MARKET: STRUCTURE
FIGURE 2 GLOBAL GENE THERAPY MARKET: MARKET GROWTH FACTOR ANALYSIS (2024-2035)
FIGURE 3 DRIVER IMPACT ANALYSIS (2024-2035)
FIGURE 4 RESTRAINT IMPACT ANALYSIS (2024-2035)
FIGURE 5 PORTER'S FIVE FORCES ANALYSIS: GLOBAL GENE THERAPY MARKET
FIGURE 6 GLOBAL GENE THERAPY MARKET, VECTOR TYPE SEGMENT, 2024-2035 (USD BILLION)
FIGURE 7 GLOBAL GENE THERAPY MARKET, BY VECTOR TYPE, 2024-2035 (USD BILLION)
FIGURE 8 GLOBAL GENE THERAPY MARKET SHARE (%), BY VECTOR TYPE, 2023
FIGURE 9 GLOBAL GENE THERAPY MARKET, GENE TYPE SEGMENT, 2024-2035 (USD BILLION)
FIGURE 10 GLOBAL GENE THERAPY MARKET, BY GENE TYPE, 2024-2035 (USD BILLION)
FIGURE 11 GLOBAL GENE THERAPY MARKET SHARE (%), BY GENE TYPE, 2024
FIGURE 12 GLOBAL GENE THERAPY MARKET, APPLICATION SEGMENT, 2024-2035 (USD BILLION)
FIGURE 13 GLOBAL GENE THERAPY MARKET, BY APPLICATION, 2024-2035 (USD BILLION)
FIGURE 14 GLOBAL GENE THERAPY MARKET SHARE (%), BY GENE TYPE, 2023
FIGURE 15 GLOBAL GENE THERAPY MARKET, DELIVERY METHOD SEGMENT, 2024-2035 (USD BILLION)
FIGURE 16 GLOBAL GENE THERAPY MARKET, BY DELIVERY METHOD, 2024-2035 (USD BILLION)
FIGURE 17 GLOBAL GENE THERAPY MARKET SHARE (%), BY DELIVERY METHOD, 2023
FIGURE 18 GLOBAL GENE THERAPY MARKET, BY REGION, 2024-2035 (USD BILLION)
FIGURE 19 GLOBAL GENE THERAPY MARKET SHARE (%), BY REGION, 2023
FIGURE 20 NORTH AMERICA MARKET ANALYSIS: GENE THERAPY MARKET, 2019-2035
FIGURE 21 NORTH AMERICA: GENE THERAPY MARKET, BY COUNTRY, 2024-2035 (USD BILLION)
FIGURE 22 NORTH AMERICA: GENE THERAPY MARKET SHARE (%), BY COUNTRY, 2024
FIGURE 23 EUROPE MARKET ANALYSIS: GENE THERAPY MARKET, 2019-2035
FIGURE 24 EUROPE: GENE THERAPY MARKET, BY COUNTRY, 2024-2035 (USD BILLION)
FIGURE 25 EUROPE: GENE THERAPY MARKET SHARE (%), BY COUNTRY, 2023
FIGURE 26 ASIA-PACIFIC MARKET ANALYSIS: GENE THERAPY MARKET, 2019-2035 (USD BILLION)
FIGURE 27 ASIA-PACIFIC: GENE THERAPY MARKET SHARE, BY COUNTRY, 2024-2035 (USD BILLION)
FIGURE 28 ASIA-PACIFIC: GENE THERAPY MARKET SHARE, BY COUNTRY, 2023 (%)
FIGURE 29 REST OF THE WORLD MARKET ANALYSIS: GENE THERAPY MARKET, 2019-2035 (USD BILLION)
FIGURE 30 REST OF THE WORLD: GENE THERAPY MARKET SHARE, BY COUNTRY, 2024-2035 (USD BILLION)
FIGURE 31 REST OF THE WORLD: GENE THERAPY MARKET SHARE, BY COUNTRY, 2024 (%)
FIGURE 32 GLOBAL GENE THERAPY MARKET PLAYERS: COMPETITIVE ANALYSIS, 2024
FIGURE 33 COMPETITOR DASHBOARD: GLOBAL GENE THERAPY MARKET
FIGURE 34 BRISTOL-MYERS SQUIBB COMPANY: FINANCIAL OVERVIEW SNAPSHOT
FIGURE 35 BRISTOL-MYERS SQUIBB COMPANY: SWOT ANALYSIS
FIGURE 36 LONZA: FINANCIAL OVERVIEW SNAPSHOT
FIGURE 37 LONZA: SWOT ANALYSIS
FIGURE 38 UNIQURE N.V.: FINANCIAL OVERVIEW SNAPSHOT
FIGURE 39 UNIQURE N.V.: SWOT ANALYSIS
FIGURE 40 BLUEBIRD BIO, INC.: FINANCIAL OVERVIEW SNAPSHOT
FIGURE 41 GENSIGHT BIOLOGICS: FINANCIAL OVERVIEW SNAPSHOT
FIGURE 42 NOVARTIS AG: FINANCIAL OVERVIEW SNAPSHOT
FIGURE 43 NOVARTIS AG: SWOT ANALYSIS
FIGURE 44 AMGEN INC.: FINANCIAL OVERVIEW SNAPSHOT
FIGURE 45 AMGEN INC.: SWOT ANALYSIS
FIGURE 46 SAREPTA THERAPEUTICS INC.: FINANCIAL OVERVIEW SNAPSHOT
Â
